An innovative biotech startup founded by researchers at Washington University School of Medicine in St. Louis has been acquired by Lunit, a leading company in developing AI-based technologies for cancer prevention and early detection. The WashU startup, Prognosia, was created to develop software that harnesses AI to analyze mammograms and more accurately predict a woman’s five-year risk of developing breast cancer.

Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, and bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The studies will be presented both in-person and online from October 17 to October 21. 

Dana-Farber investigators will also present clinical trial results that report improved quality of life for metastatic breast cancer patients; new approaches, based on early investigations, to using blood tests to guide the treatment of kidney cancer; and new ways to analyze real-world data with artificial intelligence.

Women living close to federally designated Superfund sites are more likely to develop aggressive breast cancers — including the hard-to-treat triple-negative subtype — according to new studies from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.